CPA
BPMC

Capital Performance Advisors’s Blueprint Medicines BPMC Stock Holding History

Capital Performance Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41
Closed -$3.79K – 523
2024
Q3 		$3.79K Buy
+41
New +$4.07K ﹤0.01% 1237

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Capital Performance Advisors's BPMC Position: Q4 2024 in Review

Capital Performance Advisors sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 41 shares — an estimated $3.79K sold.

Capital Performance Advisors first reported a position in BPMC in Q3 2024 and held it in 1 quarter. The position peaked at $3.79K in Q3 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

  • Capital Performance Advisors reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 41 Blueprint Medicines shares in Q4 2024, an estimated $3.79K.
  • Capital Performance Advisors first reported a position in Blueprint Medicines in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Blueprint Medicines position peaked at $3.79K in Q3 2024.
  • 345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.